| 臺大學術典藏 |
2022-04-01T08:52:51Z |
Increased risk of gastric cancer in asbestos-exposed workers: A retrospective cohort study based on taiwan cancer registry 1980-2015
|
Fang Y.-J.; Chuang H.-Y.; Pan C.-H.; Chang Y.-Y.; YAWEN CHENG; Lee L.J.-H.; Wang J.-D. |
| 臺大學術典藏 |
2022-03-24T03:27:02Z |
Community-Based Gastric Cancer Screening Coupled With a National Colorectal Cancer Screening Program: Baseline Results
|
Lee Y.-C.; Chiang T.-H.; Chiu H.-M.; Wu M.-S.; Yeh Y.-P.; Hsiu-Hsi Chen T.; Li-Sheng Chen S.; Ming-Fang Yen A.; Ching-Yuan Fann J.; Yueh-Hsia Chiu S.; Hsu C.-Y.; Chuang S.-L.; Chou K.-C.; Su W.-W.; Chen S.-T.; Liao C.-S.; Lin Y.-M.; Chang H.-C.; Hu T.-H.; Fang Y.-J.; CHANG-CHUAN CHAN; Collaborators of the Taiwan Community-Based Integrated Screening Group |
| 臺大學術典藏 |
2022-03-08T03:44:07Z |
Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma
|
SHIH-HUNG YANG; Lin L.-W.; Fang Y.-J.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:23Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:22Z |
Microelimination of chronic hepatitis C by universal screening plus direct-acting antivirals for incarcerated persons in Taiwan
|
Yang T.-H.; Fang Y.-J.; Hsu S.-J.; Lee J.-Y.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Microelimination of chronic hepatitis C by universal screening plus direct-acting antivirals for incarcerated persons in Taiwan
|
Yang T.-H.; Fang Y.-J.; Hsu S.-J.; Lee J.-Y.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T03:37:25Z |
Computer-generated surface and tone enhancements to distinguish neoplastic from non-neoplastic colon polyps less than 1 cm in diameter
|
Han M.-L.; Lee Y.-C.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Lin T.-L.; Lin L.-W.; PING-HUEI TSENG; Wu M.-S.; Wang H.-P. |
| 臺大學術典藏 |
2022-02-22T03:37:24Z |
Randomised clinical trial: High-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
|
Chen C.-C.; Lee J.-Y.; Fang Y.-J.; Hsu S.-J.; Han M.-L.; PING-HUEI TSENG; Liou J.-M.; Hu F.-C.; Lin T.-L.; Wu M.-S.; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-22T03:37:23Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; PING-HUEI TSENG; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-22T03:37:23Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; PING-HUEI TSENG; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2022-02-22T03:37:18Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; PING-HUEI TSENG; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-22T03:37:13Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; PING-HUEI TSENG; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:58Z |
Randomised clinical trial: High-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
|
CHIEN-CHUAN CHEN; Lee J.-Y.; Fang Y.-J.; Hsu S.-J.; Han M.-L.; Tseng P.-H.; Liou J.-M.; Hu F.-C.; Lin T.-L.; Wu M.-S.; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-18T08:46:57Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; CHIEN-CHUAN CHEN; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; CHIEN-CHUAN CHEN; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2022-02-18T08:46:57Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEN-CHUAN CHEN; Chen M.-J.; CHIEN-CHUAN CHEN; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-18T08:46:53Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; CHIEN-CHUAN CHEN; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; CHIEN-CHUAN CHEN; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-18T08:46:52Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; CHIEN-CHUAN CHEN; Lee Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-18T08:46:50Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; CHIEN-CHUAN CHEN; Chang C.-Y.; Chen M.-J.; CHIEN-CHUAN CHEN; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:50Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEN-CHUAN CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:49Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; CHIEN-CHUAN CHEN; CHIEN-CHUAN CHEN; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:46Z |
Systematic review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; CHIEN-CHUAN CHEN; Chen Y.-N.; CHIEN-CHUAN CHEN; Fang Y.-J.; Lin J.-T.; Wu M.-S.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:45Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEN-CHUAN CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:10Z |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chen M.-J.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Sheng W.-H.; Wang H.-P.; Wu M.-S.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-18T08:26:09Z |
Computer-generated surface and tone enhancements to distinguish neoplastic from non-neoplastic colon polyps less than 1 cm in diameter
|
Han M.-L.; Lee Y.-C.; CHIEH-CHANG CHEN; Fang Y.-J.; Lee J.-Y.; Lin T.-L.; Lin L.-W.; Tseng P.-H.; Wu M.-S.; Wang H.-P. |
